Posted by Latisha Jones on Jan 5th, 2026
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated...
More of this article »